Every fraction of function lost matters in progressive kidney disease
For the many who live with failing kidneys through no fault of diabetes, medicine has long offered limited shelter. Now, three landmark trials published simultaneously in the world's most authoritative medical journals suggest that finerenone — a drug already protecting diabetic kidneys in Australia — can slow the same quiet deterioration in patients whose disease has entirely different origins. It is a moment that asks regulators, clinicians, and health systems to consider whether a proven tool should remain confined to the population that first validated it.
- Millions of non-diabetic chronic kidney disease patients worldwide face a slow march toward dialysis or transplant with fewer pharmaceutical options than their diabetic counterparts.
- Three simultaneous publications in the New England Journal of Medicine, The Lancet, and JAMA signal an unusually coordinated and confident body of evidence — the medical community is paying attention.
- The FIND-CKD trial's measurable difference in kidney function decline — 3.3 versus 4.0 mL/min/1.73m² annually — is modest in numbers but consequential in a disease where every fraction of function lost is irreversible.
- Finerenone is currently approved in Australia only for diabetic kidney disease, meaning non-diabetic patients cannot yet access it outside clinical trials despite the new evidence.
- Bayer and research teams are expected to pursue regulatory expansion, but the pace of that process will determine how soon a waiting patient population can benefit.
A drug already prescribed to thousands of Australians with diabetic kidney disease may work just as well in people whose kidneys are failing for entirely different reasons. Three major clinical trials published this month across medicine's most prestigious journals mark the first time researchers have demonstrated that finerenone can slow kidney function decline in patients without diabetes.
The largest study, FIND-CKD, followed 1,584 non-diabetic chronic kidney disease patients over three years. Those taking finerenone experienced an annual decline in kidney function of 3.3 mL/min/1.73m², compared to 4.0 in the placebo group. In a disease where every fraction of function matters, that difference represents a meaningful slowing of an otherwise relentless deterioration.
Finerenone works by blocking a hormone receptor involved in kidney inflammation and scarring. In Australia, it is currently approved only for patients with type 2 diabetes and CKD. But kidney disease has many causes — hypertension, autoimmune conditions, genetic disorders, aging — and doctors treating non-diabetic patients have long had fewer tools, relying mainly on blood pressure control and ACE inhibitors or ARBs.
The findings, funded by manufacturer Bayer and published across the New England Journal of Medicine, The Lancet, and JAMA, carry weight precisely because of their consistency across different patient populations. Millions worldwide live with non-diabetic chronic kidney disease, many facing an inevitable progression toward dialysis or transplantation. If finerenone can genuinely slow that trajectory, it could reshape treatment for a large and underserved group.
For now, the evidence sits in the literature while nephrologists read and regulators deliberate. Non-diabetic patients cannot yet access finerenone outside clinical trials, but a push for expanded approval is widely expected. How quickly that process moves will determine whether a proven drug reaches the next population waiting for it.
A drug already prescribed to thousands of Australians with diabetic kidney disease appears to work just as well—maybe better—in people whose kidneys are failing for other reasons entirely. That's the finding of three major clinical trials published this month in some of medicine's most prestigious journals, and it marks the first time researchers have shown that finerenone, a relatively new kidney-protective medication, can slow the decline of kidney function in patients without diabetes.
The largest of these studies, called FIND-CKD, tracked 1,584 non-diabetic patients with chronic kidney disease over three years. Half received finerenone; the other half received a placebo. The difference in outcomes was measurable and consistent: patients taking the drug experienced an annual decline in kidney function of 3.3 milliliters per minute per 1.73 square meters of body surface area, compared to 4.0 in the placebo group. That gap may sound small in isolation, but in the context of progressive kidney disease—where every fraction of function lost matters—it represents a meaningful slowing of deterioration.
Finerenone works by blocking a hormone receptor involved in kidney inflammation and scarring. In Australia, it's currently approved only for patients with type 2 diabetes and chronic kidney disease, a population where earlier trials had already demonstrated its protective effects. But kidney disease has many causes: high blood pressure, autoimmune conditions, genetic disorders, and simple aging can all damage the kidneys over time. For decades, doctors treating non-diabetic kidney disease have had fewer pharmaceutical tools at their disposal, relying mainly on blood pressure control and ACE inhibitors or ARBs to slow progression.
The research team behind these trials, working with funding from Bayer—the pharmaceutical company that manufactures finerenone—published their findings across three separate journals: The New England Journal of Medicine, The Lancet, and JAMA. The breadth of publication and the consistency of results across different patient populations suggest the evidence is robust. What makes this particularly significant is that it's the first time anyone has shown finerenone's kidney-protective benefits extend beyond the diabetic population for which it was originally developed and approved.
The implications are substantial. Millions of people worldwide live with chronic kidney disease unrelated to diabetes. Many of them face a slow, inexorable decline toward kidney failure, dialysis, or transplantation. If finerenone can genuinely slow that decline—even modestly—it could change the treatment landscape for a large and underserved patient population. The next step will likely be regulatory review. Bayer and the research teams will almost certainly seek approval to expand finerenone's indication in Australia and other countries to include non-diabetic chronic kidney disease. Whether that approval comes quickly or faces scrutiny will depend on how regulators weigh the evidence and what additional data they might request.
For now, the findings sit in the medical literature, waiting. Nephrologists in Australia are reading the papers. Patients with non-diabetic kidney disease are not yet able to access finerenone outside of clinical trials, but that could change within months or years. The drug has already proven itself in one population; the question now is whether the regulatory system will move quickly enough to make it available to another.
Notable Quotes
First evidence that finerenone's benefits in chronic kidney disease extend beyond patients with diabetes— Research team behind FIND-CKD trial
The Hearth Conversation Another angle on the story
So finerenone already works for diabetic kidney disease. What's new here?
The new part is that it works for people whose kidneys are failing for completely different reasons—high blood pressure, autoimmune disease, genetic problems. Until now, nobody knew if the drug would help them.
And it does?
Yes. The trial showed patients on finerenone lost kidney function more slowly than those on placebo. Not dramatically, but measurably. Over three years, that adds up.
Why does that matter if the difference is small?
Because there aren't many drugs that slow non-diabetic kidney disease at all. Doctors have been using the same tools for decades. This is genuinely new.
So will it be approved for non-diabetic patients soon?
That's the question. The evidence is published in top journals, which is a good sign. But regulators will want to be careful. Approval could come quickly, or they might ask for more data.
Who benefits most from this?
Anyone with chronic kidney disease who isn't diabetic—millions of people. Right now they're watching and waiting to see if their doctors can prescribe it.